Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8817260 | 0.85 | GABRA1 (0.42) | GABRA1GABRB2KDM4EERN1POLB | |
| SCHEMBL15676646 | 0.83 | GABRA1 (0.64) | GABRA1GABRB2KDM4EPOLBAKR1B1 | |
| SCHEMBL29952629 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2KDM4EERN1POLB | |
| SCHEMBL617923 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2KDM4EERN1POLB | |
| SCHEMBL5035892 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2ERN1ALDH1A1L3MBTL1 | |
| SCHEMBL31450219 | 0.76 | ERN1 (0.59) | ERN1MEN1KMT2ALMNA | |
| SCHEMBL17541404 | 0.76 | ERN1 (0.59) | ERN1MEN1KMT2ALMNA | |
| SCHEMBL3957273 | 0.76 | SRD5A1 (0.45) | GABRA1GABRB2KDM4EERN1POLB | |
| SCHEMBL9800334 | 0.76 | POLB (0.49) | GABRA1GABRB2KDM4EERN1POLB | |
| SCHEMBL2575094 | 0.76 | GABRA1 (0.43) | GABRA1GABRB2KDM4EPOLBAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | GABRA1 4558/4885GABRB2 4404/4885KDM4E 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.